Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily summary: Donald Trump sets the pace for the market
Delays at Nvidia: Is the Kyber project at risk?
NATO Secretary General’s comments support European defense stocks
US OPEN: ISM and semiconductors in the spotlight after the long weekend